A Catteau Selected Research

(4- ((1- (3- fluorophenyl)methyl)- 1H- indazol- 5- ylamino)- 5- methylpyrrolo(2,1- f)(1,2,4)triazin- 6- yl)carbamic acid 3-morpholinylmethyl ester

1/2019	Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.
2/2012	Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A Catteau Research Topics

Disease

2	Colonic Neoplasms (Colon Cancer) 09/2020 - 01/2020
2	Neoplasms (Cancer) 01/2019 - 02/2012
1	Infertility (Sterility) 01/2016
1	Exanthema (Rash) 02/2012
1	Asthenia 02/2012
1	Anorexia 02/2012
1	Diarrhea 02/2012
1	Meningeal Carcinomatosis 02/2008

Drug/Important Bio-Agent (IBA)

2	Oxaliplatin (Eloxatin)FDA LinkGeneric 09/2020 - 01/2020
2	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2019 - 02/2012
2	(4- ((1- (3- fluorophenyl)methyl)- 1H- indazol- 5- ylamino)- 5- methylpyrrolo(2,1- f)(1,2,4)triazin- 6- yl)carbamic acid 3-morpholinylmethyl esterIBA 01/2019 - 02/2012
1	LeptinIBA 01/2016
1	AdipokinesIBA 01/2016
1	Pharmaceutical PreparationsIBA 02/2012
1	Biomarkers (Surrogate Marker)IBA 02/2012
1	ErbB Receptors (EGF Receptor)IBA 02/2012
1	GadoliniumIBA 02/2008

Therapy/Procedure

1	Adjuvant Chemotherapy 01/2020
1	Therapeutics 01/2020
1	Aftercare (After-Treatment) 02/2012